shares sank after the company reported disappointing clinical trial results on its anti-inflammatory drug for cardiac surgery patients. Shares fell 4.3% to $2.70.
( KG) fell after disappointing trial data were released. According to a study presented in a meeting of the European Association for the Study of Diabetes and published in the
New England Journal of Medicine
, the incidence of type 2 diabetes development wasn't significantly different between patients taking the company's drug Ramipril compared with those taking a placebo. Shares were down 3% to $16.05.
( BTRX) rose after the company said it's planning a private stock offering worth $25 million. The company plans to sell around 4.8 million shares at $5.25 each to institutional investors. Shares were trading 4.3% higher at $5.64.
( SGP) shares advanced after a report that the company is "seriously considering" an attempt to merge with another drug giant,
. Schering was up 1.3% to $21.40, and Bristol's shares were up 1.6% to $25.08.
( DNA) gained 1.5% to $79.29 after Caris initiated coverage of the stock with a strong buy rating.
Other movers were
, whose shares gained 14.8% to $2.80,
, up 7.9% to $10.53,
, ahead by 1.4% to $12.63, and
( MSHL), 6.8% higher to $3.
slipped 0.5% to $55.11,
was down 7.1% to $1.19,
was sinking 8.5% to $5.17,
( NTMD) was 5.3% lower to $2.48, and
was down 2.9% to $13.01.